Synthetica Pioneering (Shengbao Bio)
深圳市生葆生物科技有限公司
A SIAT-incubated synthetic-biology startup developing engineered living bacterial therapeutics for solid tumours — strong investors and synbio pedigree, but far from pilot-fermentation manufacturing for a topical product.
- Location
- SIAT-incubated (Shenzhen; precise district not verified) · Shenzhen
- Visit window
- From the Nanshan base · Jul 13–31
- Source status
- low confidencecandidate
Next action
Verify source confidence before outreach; then use the visit objective as the meeting ask.
Why now: Visit window · From the Nanshan base · Jul 13–31
What they do
A SIAT/CAS spin-off founded in 2023, focused on gene-circuit engineering and precise control of genes and payloads to treat disease — currently developing oncolytic bacterial therapies for solid tumours. Its strength is quantitative synthetic biology.
It is a therapeutics R&D / pipeline company, not a contract manufacturer or ingredient-supply platform.
Why it matters
Low fit. A SIAT/iSynBio-network synbio contact only — quantitative synthetic biology and gene-circuit engineering are adjacent in spirit to Pure Advance's engineered-microbe platform, but the oncolytic-bacterial-therapy focus serves neither the agri-biocontrol lead nor the secondary Coolvex topical line.
The live-biotherapeutic regulatory burden is high and they are not a service provider. Keep purely as an ecosystem/synbio-network contact; deprioritise for this trip.
Visit objective & route
Treat as a low-priority ecosystem/synbio-network touchpoint; if engaged at all, confirm whether any manufacturing or ingredient-supply service exists (expected none) and gauge whether their quantitative synbio / gene-circuit expertise could matter to a future Pure Advance engineered-microbe effort.
Approach route
Only via the SIAT / iSynBio network, if at all.
Talking points
- Is there any manufacturing or ingredient-supply service, or is this purely a therapeutics R&D pipeline (expected: no service)?
- Could your quantitative synthetic-biology / gene-circuit expertise ever apply to engineered-microbiome or live-biotherapeutic work Pure Advance might pursue later?
- Is the SIAT / iSynBio network the better route to reach you?
- Bring: Pure Advance one-pager (AI-accelerated microbial biocontrols); NDA template.
Open questions
- Confirm there is no manufacturing-service offering (expected: none).
- Precise Shenzhen location / district not yet verified.
- Leadership not yet identified.
- Re-check appointment availability before travel.
Risks & unknowns
- Therapeutics R&D pipeline company, not a contract manufacturer or ingredient supplier — no direct service offering.
- High live-biotherapeutic regulatory burden.
- Appointment-only and low priority; best reached only via the SIAT/iSynBio network.
- Low confidence — contact details and availability need re-checking before travel.
Public sources
Private-pack boundary